19 Aug 2021
Congenica signs distribution agreement with ATC Healthcare in Turkey
Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a new distribution agreement with ATC Healthcare (“ATC”), a leading Turkish business investing in advanced technologies in the fields of molecular diagnosis and life sciences.
ATC Healthcare distributes on behalf of major international providers of molecular diagnostic solutions. Its customers work in academic laboratories and clinical diagnostics and are based across Turkey.
The agreement represents the entry of Congenica’s clinical decision support software into Turkey, a major global market with a population of 84 million people. Turkey has a well-established national genome project that aims to sequence 100,000 genomes from healthy individuals as well as from rare and complex disease patients to promote better health for future generations.
ATC will distribute Congenica’s clinical decision support software platform for use in the interpretation of complex genomic data with a focus on rare diseases. Congenica’s leading technology platform enables the rapid analysis and interpretation of complex genomic data, allowing the delivery of personalised medicine at scale.
Willem Haagmans, Vice-President Sales EMEA at Congenica, said:
“This latest agreement with ATC Healthcare highlights our ongoing expansion into new global markets as we accelerate the rollout of our leading genomic analysis platform. Turkey is recognised as a leader in genomics with a strong focus on using clinical genomics to transform healthcare. ATC has an excellent reputation in molecular diagnostics with strong links in the region, which we believe will enable the rapid uptake of Congenica’s software.”
Burcu Torun, Managing Partner & GM at ATC Healthcare, said: “At ATC we are committed to partnering with the highest quality businesses in the molecular diagnostics space as we enable their advanced technologies to become accessible to our customers in Turkey. With Turkey’s national genome project gathering pace we believe Congenica’s platform will enable clinical genomics to be incorporated into routine clinical practice to transform the lives of patients.”